All.Can at two years:
annual report

The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial (in kind) support from Intacare and Goings-On.
Foreword

All.Can has grown to become a truly global family in its second year, committed to eliminating inefficiency in cancer care.

In 2018 our global membership doubled, and we now have more than 150 experts donating their time, energy and knowledge – all determined to make a difference. Our multi-stakeholder composition of patient advocates, healthcare professionals, industry, providers and researchers is our greatest strength, allowing us to ground our work in the realm of individual and local experience. In everything we do, we recognise that our success is founded in these partnerships.

All.Can has joined the EU Innovative Partnership for Action Against Cancer (iPAAC), and is collaborating with the International Consortium for Health Outcomes Measurement. The past year has been filled with research to amass evidence and recommend concrete solutions for governments to implement, and the key understandings and solutions come from their real-world data.

Unprecedented pressure on our healthcare systems means that we must look urgently at ensuring limited funds are spent wisely, waste is reduced, and care is delivered with value to patients and healthcare systems. The All.Can patient survey, the first of its kind, helps us to understand the emotional and practical factors of this, including the patient perspective on where inefficiencies exist.

Ultimately, our work is directed towards changing lives. We strive to help cancer patients experience the care they deserve, and support our healthcare systems to achieve the full potential of patient-centred care, efficiency and sustainability. While problems of inefficiency may be universal, All.Can understands that every country faces its own barriers and challenges – resulting in the need for unique solutions around the globe. Together with our national initiatives, we can bring meaningful change worldwide to cancer patients at an individual level.

As I look to the future, I envision us focusing on our core mission – to change cancer care for patients, utilising both the research from this past year and our collective knowledge built since the inception of All.Can. With an upcoming year of change in Europe, I look positively at the opportunities it will bring for the All.Can family to achieve long-term commitment to change.

I believe that, together, we can usher in a new era of accessible and sustainable cancer care – with patients at the heart of its very essence.

Alex Filicevas
Head of EU Affairs, European Cancer Patient Coalition; member of All.Can international steering committee
All.Can was launched in December 2016, as a multi-stakeholder initiative striving to improve efficiency in cancer care by focusing on what matters to patients. During its first year, All.Can established itself with a policy report, peer-reviewed publication and successful policy events across Europe, along with the development of the first national All.Can initiatives.

This document celebrates all that we have achieved in our second year, and looks at how we plan to begin translating the data we have been collecting into concrete policy action to improve cancer care for all.

‘Why focus on efficiency? Because every euro, pound or penny we spend on something that isn’t improving patient outcomes is money that’s being wasted. So there’s a moral imperative to do this.’

Vivek Muthu
Managing Director, Marivek Healthcare Consulting; member of All.Can international steering committee
What is All.Can?

All.Can (www.all-can.org) is an international multi-stakeholder initiative which was set up to identify ways we can optimise the efficiency of cancer care by focusing on improving outcomes for patients.

The All.Can family includes All.Can international and several national All.Can initiatives. This document focuses primarily on All.Can international, with brief highlights from the initiatives around the world.

We believe that what matters to patients must always be at the heart of cancer care, and that all stakeholders must work together to ensure we allocate resources to prioritise interventions, technologies and models of care that improve patient outcomes, above all other considerations. This is key to the sustainability of cancer care.

We aim to drive sustainable healthcare solutions for everyone affected by cancer

A world in which patients are always at the heart of sustainable cancer care
Where have we come from?

All.Can was launched at the European Parliament on 6 December 2016. In two years, it has grown from an idea to a fully operational and expanding movement, with membership from key figures in the world of cancer, leading engaging events and embarking on exciting research projects to provide evidence-based recommendations to those with decision-making power.

Around the globe, All.Can brings together almost 150 members from all aspects of the cancer care pathway – through both All.Can international and the national All.Can initiatives. As of January 2019, there were national initiatives fully established in nine countries, with a further four countries in advanced stages of development.

The past two years have been busy with publications, events and the undertaking of complex international research projects – bringing us to an exciting juncture where we can build on the findings of our research and engage our members and other organisations to help share and implement greater efficiency in cancer care across the world.
Our members

All.Can international is made up of 26 members representing a broad scope of sectors and a vast range of knowledge and expertise.

All.Can international is currently funded by five private companies: Bristol-Myers Squibb (main sponsor), MSD, Amgen, Johnson & Johnson (sponsors) and Varian (contributor). We also have two knowledge partners which contribute to All.Can in kind (non-financial): Intacare and Goings-On.

We continue to engage with a variety of healthcare organisations, including private-sector companies, to join All.Can. We feel it is important that our membership reflects the broad spectrum of actors involved in cancer care. A key goal for 2019 is to expand the funding base beyond the pharmaceutical sector, engaging further partners in the data and information technology space in particular. We were delighted to welcome Varian Medical Systems – a radiation oncology treatments and software company – as an All.Can funding partner in 2018.
‘Our collaboration with All.Can ensures our research retains a core focus on what matters most to patients. Our valued partnership enables us to support one another in the global promotion of innovative models of quality, efficiency and value for all stakeholders associated with cancer care.’

Matthew Hickey
Founding Director and CEO, Intacare International Ltd; member of All.Can international

‘It’s very important to work together when we are dealing with an area like cancer. There’s no single specialty that can do everything.’

Matti Aapro
Clinique de Genolier, Switzerland; member of All.Can international steering committee

‘Sustainable cancer care starts with what matters most to individual patients and families. Aligning care with patient goals carries tremendous potential for quality of life and efficiency. We joined All.Can because we share this focus and acknowledge joint efforts can help patients get that care.’

Petra Hoogendoorn
Founder and Director, Goings-On; member of All.Can international
Our governance

All.Can international is fully led by its members, with a steering committee holding the decision-making role.

Through involvement in working groups, members are engaged in all major decisions linked to All.Can international’s activities. Members also approve the strategic plan, which is devised by the steering committee, and have full editorial control over all publications.

All.Can international prides itself on its multi-stakeholder nature. All members’ opinions and contributions are valued – and considered equal – irrespective of membership status. Our governance structure (pictured right) guarantees All.Can’s independence, transparency and multi-stakeholder engagement in the decision-making processes.

In 2018, we established our full Terms of Reference, which are available on our [website](#).
Ultimate decision-making power rests with the international steering committee. The steering committee includes representatives of All.Can constituencies including patient advocacy, healthcare professionals, research, providers and industry. Election to the steering committee is via majority vote by all All.Can international members.

All.Can international steering committee 2018–19:

- Matti Aapro
  Clinique de Genolier, Switzerland
- Tit Albreht
  Slovenian Public Health Institute
- Kathy Barnard
  Save Your Skin Foundation Canada
- Alex Filicevas
  European Cancer Patient Coalition
- Vivek Muthu
  Marivek Healthcare Consulting
- Kathy Oliver
  The International Brain Tumour Alliance
- Titta Rosvall-Puplett
  Bristol-Myers Squibb
- Karin Steinmann
  Amgen

Funding partners on the steering committee have one vote collectively, rather than one vote each.
All.Can’s second year saw the expansion of the international initiative with new members, collaborations and successful events across Europe, along with the addition of five new national initiatives to the All.Can family.
‘It’s crucial for all sectors to collaborate. Cancer is such a challenging and difficult disease, and none of us can fight it on our own. The silo approach has no place in cancer care.’

Kathy Oliver
Founding Co-Director and Chair, the International Brain Tumour Alliance; member of All.Can international steering committee
Highlights of the year

MEPs Against Cancer seminar

In January, All.Can joined Lieve Wierinck MEP, the Association of European Cancer Leagues (ECL), the European CanCer Organisation (ECCO) and the European Cancer Patient Coalition (ECPC) to host a seminar with the MEPs Against Cancer (MAC) group at the European Parliament. More than 50 attendees heard powerful examples of efficiency and innovation in cancer care, focusing on what matters to patients with the aim of improving outcomes. The take-home message was that sustainable cancer care cannot be achieved by a single stakeholder alone, and that EU nations must exchange best practices and innovative solutions in cancer care.

All.Can global summit

The first ever All.Can global summit brought together more than 50 attendees from 15 countries to share ideas and best practice. Representatives of All.Can national initiatives led discussions on country-level research, the importance of collaboration, the All.Can international patient survey and creating synergies between national initiatives and All.Can international. The global summit was the first time representatives from All.Can international and the national initiatives have come together to share their experiences, and provided a blueprint for how the All.Can family can continue to work together in future.

‘I challenge you to ask yourself: How can we achieve more efficient and sustainable cancer care together? And what is my individual role in helping to make this a reality?’

Lieve Wierinck MEP
Opening address at MAC seminar at the European Parliament, 31 January 2018
The All.Can patient survey is a core pillar of our research. Throughout 2018, All.Can worked with Quality Health to run the survey in ten countries around the world.

The survey was completed by current and former cancer patients, or their carers. The questions asked for respondents’ views on what needs to improve or change in the delivery of care for cancer patients, throughout the care pathway.

Findings will help identify the greatest opportunities to improve efficiency in cancer care in a way which is most meaningful to patients. All.Can UK released early findings from the UK pilot in late 2018, with the official report of findings from All.Can international due to be published in April 2019.

‘It’s been really exciting to work on the All.Can patient survey. We’ve previously been asked to run many cancer patient experience surveys in many countries – but rarely on this scale, and never asking directly about waste and inefficiency.’

Daniel Ratchford
CEO, Quality Health
All.Can international is a collaborating partner in the Innovative Partnership for Action Against Cancer (iPAAC).

iPAAC is a European Commission-funded Joint Action that connects almost 44 partners across Europe to improve cancer control. It works to build on the deliverables of the previous CANCON Joint Action, and to implement innovative approaches to cancer control.

The project is running from 2018 to 2020, with the final output being the delivery of a Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support member states to implement the recommendations.

All.Can international will be contributing to the Work Package 8, addressing the 'Challenges in Cancer Care'. The programme of work is currently in development.

For more information, please visit https://www.ipaac.eu/
All.Can international is also partnering with the International Consortium for Health Outcomes Measurement (ICHOM) on the Improving Value in Cancer Care study.

All.Can and ICHOM are leading this study to provide value-based care for patients with breast and lung cancer. The goal is to measure the outcomes and costs associated with lung and breast cancer care, with a view to identifying what contributes to variations in outcomes and overall efficiency. These data will be used to track and measure quality improvements within these cancer care communities.

The study has identified eight sites for breast cancer and six for lung cancer – each of which sees more than 200 new cancer patients every year – that will participate in the project. The participating sites are located in Belgium, France, Italy, Portugal, Spain and Switzerland.

Findings from the study will be released at the end of 2019.

‘The ICHOM–All.Can Improving Value in Cancer Care study represents a truly exciting opportunity to improve the quality and efficiency of care in breast and lung cancer, and inspire other providers to start measuring the value they are creating for their patients.’

Neil Bacon
President and CEO, ICHOM
2018 in numbers

During the course of its second year, All.Can international...

- gained 6 new members, bringing the total to 26
- engaged with over 4,000 patients with the All.Can patient survey, which was produced in 11 languages and gained responses from more than 30 countries
- attended 8 events, which included hosting a session at European Health Forum Gastein for the second consecutive year
- welcomed 5 new national initiatives across three continents, bringing the total to nine
- gained 6 new members, bringing the total to 26
- and there are now more than 150 All.Can members worldwide
- with a further 4 national initiatives in advanced stages of development as 2019 began

presented 1 poster at the European Society for Medical Oncology (ESMO) congress, in collaboration with ICHOM
All.Can in print...

Although the focus of its second year has been data collection, All.Can international has continued to build its public profile by publishing articles. Both Open Access Government and Eurohealth published features from All.Can in 2018, helping to spread the word about our mission to improve efficiency in cancer care by focusing on what matters to patients.

The news media also took an interest in All.Can in 2018, after first findings from the UK pilot of the patient survey were released by All.Can UK. The news was covered in British outlets including Pharma Times and national newspapers the Independent and The Sun.

...and in video

At the European Health Forum Gastein in October, All.Can international hosted a session on ‘Patient insights for sustainable care – improving efficiency in care for all’. A video about the session was released online.

We also launched a series of short clips in which All.Can international members discuss some of the initiative’s most important themes. These clips were shared on social media, helping to reach new audiences with our key messages.
All.Can understands that, while problems of inefficiency may be universal, the solutions to those problems will be unique to each country.

That is why we support the development of national initiatives around the world, to tackle inefficiency at a national level. Each initiative is fully independent and made up of members – and targeting policymakers – relevant to that country. We are all, however, still working toward the same goal: tackling inefficiency by putting the patient first.

From four countries at the beginning of 2018, All.Can has now expanded to a total of nine fully established national initiatives across three continents. The next two pages give details of the highlights from each country over the last year.
All.Can Australia launched in February on World Cancer Day, with a focus on highlighting key areas for improvement in value-based care across all cancer stages. Having established a baseline understanding of the patient journey through the All.Can patient survey, it will publish a report in June 2019 aiming to evaluate the Australian cancer care system and identify efficient allocation of resources to most benefit patients.

Find out more about All.Can Australia

All.Can Canada launched in April, surveying multiple stakeholder groups to prioritise nationwide and province-specific cancer care inefficiencies, and gathering real-world data through the All.Can patient survey. It plans to publish a report in 2019 and engage health policy decision-makers.

Find out more about All.Can Canada

All.Can Belgium launched in June and is currently working on a policy brief, taking the opportunity of upcoming national elections to draw attention to the need for greater efficiencies in cancer care in Belgium. It will host an official launch event in March 2019, and has established a newsletter to help spread the All.Can message.

Find out more about All.Can Belgium

All.Can Germany completed its year-long roadshow in August. The roadshow travelled across the country, making ten stops to explore key topics including diagnosis, psycho-oncology, cancer survivorship and translational research.

Find out more about All.Can Germany

All.Can Poland has developed a report on the optimisation of cost and time of diagnosis and treatment of ovarian and lung cancer, to be published in March 2019. The data will be presented in Parliament and at a number of congresses and conferences.

Find out more about All.Can Poland
All.Can Switzerland, which launched in July, has initiated three projects with the goal of improving Swiss cancer care. In 2019, All.Can Switzerland will be legalised as ‘non-profit association’. Its activities and governance documents (e.g. by-laws) will be made public soon.

Find out more about All.Can Switzerland

All.Can Spain launched in July and has already identified 11 inefficiencies that it will work towards eliminating by 2021. It is planning to demonstrate recommendations throughout all autonomous regions in Spain.

Find out more about All.Can Spain

All.Can Sweden released its policy report in June, outlining its key policy recommendations. It is particularly focusing on the role of data and technology in improving the efficiency of cancer care.

Find out more about All.Can Sweden

All.Can UK hosted a best-practice webinar in February, targeting service providers in the National Health Service. In October, it published a new report identifying five common barriers to the adoption of best practice, and case studies that have overcome them. It also released the first findings of the UK pilot of the All.Can patient survey in December at a key cancer conference.

Find out more about All.Can UK
What next for All.Can?

Findings from the first ever international patient survey on efficiency in cancer care will be released in early 2019. The survey responses will help us to demonstrate the patient perspective on where there are concrete opportunities to increase efficiency in cancer care.

Another project that is the first of its kind, the All.Can–ICHOM Improving Value in Cancer Care study will also shed light on factors contributing to variations in patient outcomes in lung and breast cancer care, so that we may deliver better value to patients throughout the care pathway.

During 2019 and beyond, we look forward to continuing to work with experts across the field of cancer care, and in other areas of healthcare and policy. In the years to come, we will work to bring our unique insights and research findings to policymakers all over the world.

We encourage you to get in touch if you share our vision and are interested in working with us. Only by working together can we solve the challenges of cancer care and achieve positive change for everyone affected by cancer.
Join us. Work with us. Together, we All.Can.

www.all-can.org
Twitter: @AllCanGroup
Facebook: @AllCanGroup
LinkedIn: All.Can
secretariat@all-can.org

The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial (in kind) support from Intacare and Goings-On.